# Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

> **NCT06895031** · PHASE2 · RECRUITING · sponsor: **Guangzhou JOYO Pharma Co., Ltd** · enrollment: 210 (estimated)

## Conditions studied

- Solid Tumor
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)

## Interventions

- **DRUG:** JYP0015

## Key facts

- **NCT ID:** NCT06895031
- **Lead sponsor:** Guangzhou JOYO Pharma Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06895031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06895031, "Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06895031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*